Author:
Heidenreich Axel,Gillessen Silke,Heinrich Daniel,Keizman Daniel,O’Sullivan Joe M.,Carles Joan,Wirth Manfred,Miller Kurt,Reeves John,Seger Monica,Nilsson Sten,Saad Fred
Funder
Pharmaceutical Division of Bayer
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Genetics,Oncology
Reference23 articles.
1. Henriksen G, Breistol K, Bruland OS, et al. Significant antitumor effect from bone-seeking, alpha-particle-emitting (223)Ra demonstrated in an experimental skeletal metastases model. Cancer Res. 2002;62:3120–5.
2. Bruland OS, Nilsson S, Fisher DR, Larsen RH. High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223Ra: adjuvant or alternative to conventional modalities? Clin Cancer Res. 2006;12:6250s–7s.
3. Suominen MI, Fagerlund KM, Rissanen JP, et al. Radium-223 inhibits osseous prostate cancer growth by dual targeting of cancer cells and bone microenvironment in mouse models. Clin Cancer Res. 2017;23:4335–46.
4. Parker C, Gillessen S, Heidenreich A, et al. Cancer of the prostate: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(suppl 5):v69–77.
5. NCCN guidelines-Prostate cancer version 1. 2018.
https://www.nccn.org
.
Cited by
38 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献